Navigation Links
Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
Date:2/12/2009

- Discovery Could Lead to the Development of a Next-Generation Assay to Improve Diagnosis and Treatment of Ovarian Cancer -

FREMONT, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Vermillion, Inc. (OTC Bulletin Board: VRML), a molecular diagnostics company, today announced that the U.S. Patent Office (USPTO) has issued a notice of allowance to the Company for the discovery of hepcidin as a biomarker for ovarian cancer. The discovery could ultimately lead to the development of an improved, next-generation assay that might provide physicians with additional, valuable information to diagnose ovarian cancer.

"The notice of issuance of this patent validates the strength of our approach in the development of innovative molecular diagnostics," said Eric T. Fung, M.D., Ph.D, Chief Scientific Officer of Vermillion and co-inventor. "This patent comprises an important component of our ovarian cancer patent portfolio."

The patent also covers the measurement of hepcidin by a variety of methods, including mass spectrometry and other immunoassay approaches.

About Vermillion's Ovarian Cancer Diagnostic Program

Vermillion has multiple ovarian cancer diagnostic tests in development. The most advanced of Vermillion's programs is the OVA1 test, which is designed to utilize a panel of biomarkers to help identify women with a higher likelihood of malignancy so they can be referred to a gynecologic oncologist for their initial surgery. Vermillion filed a 510(K) Application with the U.S. Food and Drug Administration for its OVA1(TM) Test in June 2008.

Additionally, studies are underway to develop tests with the capability of detecting early-stage ovarian cancer, predicting prognosis and recurrence, and identifying women considered at high-risk for the disease.

Vermillion's premier diagnostic development program is being conducted with several leading collaborators at T
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vermillion Announces Receipt of NASDAQ Panel Decision
2. Vermillion and Stanford Scientists Receive Best Research Award From the PAD Coalition
3. Vermillion Retains ThinkPanmure to Assist in the Evaluation of Potential Strategic Alternatives
4. Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission
5. Vermillion Announces First Quarter 2008 Financial Results and Business Progress
6. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
7. Vermillion Announces Appointment of John Hamilton to Board of Directors
8. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
9. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
10. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
11. Vermillion Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Global & USA BioSimilar Market Analysis to 2021" ... US Biosimilar market will be initiated in September as ... will the global market react? Will biosimilars explode into ... save the US economy up to $250 billion within ...
(Date:8/28/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, ... June 30, 2015, corporate highlights, and near-term milestones.  ... available at www.sedar.com ,  www.edgar.com ... "RepliCel expects to launch its RCS-01 treatment for ...
(Date:8/27/2015)... ... , ... Capital Edge Consulting , a nationwide consulting firm that specializes ... ranking as one of the top 5000 companies listed on the 2015 Inc. ... , “It is truly an honor to be recognized as one of America’s fastest ...
(Date:8/27/2015)... , Aug. 27, 2015  Asterias Biotherapeutics, Inc. (NYSE ... field of regenerative medicine, today announced that executives from ... the month of September.  , ... Rodman & Renshaw,s 17th Annual Global Investment Conference on ... the St. Regis Hotel in New York ...
Breaking Biology Technology:Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2
... Pharmos Corporation,(Nasdaq: PARS ) today reported results for the ... loss of $2.7 million, or $0.10 per share,for the second ... or,$0.18 per share, in the second quarter 2007. Cash and ... decrease in net loss for the second quarter 2008 is ...
... Aug. 7 Anesiva,Inc. (Nasdaq: ANSV ) today ... six months ended June 30, 2008., "The 2008 ... we,introduced Zingo(TM) in the U.S. pediatric hospital market," said ... I,m pleased,to report that our Phase 3 trials of ...
... announced that it,has extended its current offer to purchase ... Purchase Warrants, Class 1 and Class B Common Stock,Purchase ... time, on,Friday, August 15, 2008. The offer was scheduled ... August 7, 2008., The extension will provide Warrant ...
Cached Biology Technology:Pharmos Corporation Reports 2008 Second Quarter Results 2Pharmos Corporation Reports 2008 Second Quarter Results 3Pharmos Corporation Reports 2008 Second Quarter Results 4Pharmos Corporation Reports 2008 Second Quarter Results 5Anesiva Announces Second Quarter 2008 Financial Results and Update 2Anesiva Announces Second Quarter 2008 Financial Results and Update 3Anesiva Announces Second Quarter 2008 Financial Results and Update 4Anesiva Announces Second Quarter 2008 Financial Results and Update 5Anesiva Announces Second Quarter 2008 Financial Results and Update 6Anesiva Announces Second Quarter 2008 Financial Results and Update 7Anesiva Announces Second Quarter 2008 Financial Results and Update 8
(Date:8/12/2015)... 12, 2015  New research unveiled at Black ... phones to steal users, fingerprints. Information released today ... fingerprint scanners on mobile devices, making the security ... biometrics on mobile devices, HYPR Corp. recently released ... authentication systems with strong cryptographic security. More information ...
(Date:8/10/2015)... 2015 The latest 364 page report ... of the global border security market . Visiongain ... in 2015. Now: Border security is hard to ... the business critical issue you need to know about - ... objective analysis of how this will impact your company and ...
(Date:8/5/2015)... According to a new market ... Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, Education, ... to 2020", published by MarketsandMarkets, defines and segments the ... segments. The global PIAM Market is estimated to grow ... 2019, at a CAGR of 14.9 % from 2014 ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... protein regulates secretion levels in the fruit fly's salivary ... the May 15 issue of Development, the finding improves ... is a critical ability of certain glands and cell ... researchers discovered that a protein called CrebA single-handedly controls ...
... skin cancer, researchers at the Huntsman Cancer Institute at the ... gene found in up to 30 percent of human tumors. ... in cell signaling, or communication among cells. When mutated, however, ... shown to promote the growth of cancers in the pancreas, ...
... gene therapy can promote the growth of new "insulation" around ... new study shows. The treatment, which mimics the activity of ... and electrical conduction from the brain to the leg muscles. ... spinal cord injury in humans. The study was funded in ...
Cached Biology News:Study: Well-known protein helps stem cells become secretory cells 2Scientists inhibit cancer gene 2Combination therapy leads to partial recovery from spinal cord injury in rats 2Combination therapy leads to partial recovery from spinal cord injury in rats 3
...
2ndGen Predilute antibody for staining tissue sections. Optimized for use with Zymeds Histostain-PLUS, NBA, HistoST5050, and Cap-Plus IHC Kits.Labeling: ASR...
... degradation of single-stranded DNA and RNA endonucleolytically ... nuclease prefers ssDNA over dsDNA by 30,000-fold, ... double-stranded DNA from both ends (1,2). Mung ... mapping studies (3,4), for flushing staggered ends ...
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
Biology Products: